Arrowhead Pharmaceuticals Inc. (ARWR): Spotlighting on The Keys fundamentals


Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) changes shares on Tuesday trading session, with a change of -0.59% or -$0.26 shares. The trading starts at $44.00 and closed at $44.38 throughout the day. The trading session low price was $43.29 and day high was $44.63 on Tuesday, August 04. After the session, the Healthcare sector daily volume shifted to 0.5 million while its average volume is 1.12M. In other hand, the ARWR market cap reached to $4.74B. While, its current target price is $61.70.

On May 7, 2020, BRIEF-Arrowhead Pharma Reports Quarterly Loss Per Share Of $0.20. According to the news reported on Reuters, * ARROWHEAD PHARMACEUTICALS REPORTS FISCAL 2020 SECOND QUARTER RESULTS

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is down -3.05% and up 0.91% for month. Its quarterly performance was 24.63% above, while its half year performance is up 0.50%. ARWR yearly performance stood at positive 61.97% and fall -30.44% for year-to-date. Current recommendation for Arrowhead Pharmaceuticals Inc. is 2.00.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. ARWR EPS (TTM) for 12-month is 0.10. EPS for this year is 205.90%, while for the next year its value is -0.97. Sales growth for the current quarter is 60.80 while its EPS Q/Q reached -180.10%. It has an EPS of 20.60% up for past five years and for the next five years will be up 7.33%.

Let’s take a look on the analyst recommendations on ARWR for the current month and previous month. For the current month, 6 of 9 analysts recommend stock as Buy while 0 as Sell, 1 as overweight, 0 as underweight and 2 as Hold. As compared with the previous month ratings, 9 analysts participate in stock recommendation. Out of 9, 0 rated it sell, 5 rated it as Buy and 3 as Hold Ratings.

The insider ownership moved to 4.10% and institutional holding shifted to 65.60%.

The company posted an EPS (TTM) of 0.10. According to the most recent quarter report on (Jun 2020), 10 analysts estimated an average EPS of -0.12, while 0.21 EPS posted a year ago period. Analyst Estimated EPS for ARWR published in the report was -$0.41 – $0.65 during the same period. Comparing with last year, the average estimated EPS was 0.21 which is higher than -0.2 which was posted for recent quarter EPS.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for ARWR rise 2.79% for period of 200 days. SMA for 50 days was 8.28% which is showing green signal, while SMA-20 was -5.26%. The moving average value for Arrowhead Pharmaceuticals Inc. (ARWR) is 8.4M and 10.12% for 200 and 50 days respectively.

Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in ARWR stock. On Jun 25, Anzalone Christopher Richard, Chief Executive Officer, sold 100,000 trading shares at the cost of $38.81, which valued at 3.88 million. On Jun 15, De Backer Marianne, Director, bought 500 shares at the cost of $31.33, with total shares of 16,500. On May 12, PERRY MICHAEL S, Director, sold 36,000 shares at the cost of 35.83. After this transaction, PERRY MICHAEL S total shares reached to 8,000 which valued at 1.29 million.